<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/8F39BF6D-C072-41A7-902E-644FEFC1BC8A"><gtr:id>8F39BF6D-C072-41A7-902E-644FEFC1BC8A</gtr:id><gtr:name>Djs Antibodies Ltd</gtr:name><gtr:address><gtr:line1>Cherwell Innovation Centre 77 Heyford Park,Upper Heyford</gtr:line1><gtr:city>Bicester</gtr:city><gtr:postCode>OX25 5HD</gtr:postCode><gtr:region>South East</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8F39BF6D-C072-41A7-902E-644FEFC1BC8A" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>8F39BF6D-C072-41A7-902E-644FEFC1BC8A</gtr:id><gtr:name>Djs Antibodies Ltd</gtr:name><gtr:address><gtr:line1>Cherwell Innovation Centre 77 Heyford Park,Upper Heyford</gtr:line1><gtr:city>Bicester</gtr:city><gtr:postCode>OX25 5HD</gtr:postCode><gtr:region>South East</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>24998.0</gtr:offerGrant><gtr:projectCost>42000.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/96BC6A27-B721-484F-A922-21C2415E9080"><gtr:id>96BC6A27-B721-484F-A922-21C2415E9080</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Llewellyn</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=700639"><gtr:id>A2FE72F5-54A4-4FC6-A2ED-287D6F444B9A</gtr:id><gtr:title>Defining the market for monoclonal antibody development against GPCRs</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>GRD Proof of Market</gtr:grantCategory><gtr:grantReference>700639</gtr:grantReference><gtr:abstractText>We have devised a new strategy for the discovery of a class of medicines called monoclonal
antibodies (mAbs). mAbs are medical ?magic bullets? that can specifically target diseases in
our bodies, and have been very successful in the treatment of conditions such as inflammatory
disease and cancer. Unfortunately, however, some of the most attractive disease targets for
mAbs, such as multi-pass membrane proteins, have not been targeted. The reason for this is
technical, with current methods having very low success rates and utilising technologies
which can cost hundreds of thousands of pounds and take years to develop. We have
developed a platform for mAb discovery that sidesteps the reliance on these inefficient
techniques and have shown it to be highly successful in early experimental work. This means
that we have the potential to generate mAbs against disease targets for which traditional
methods do not work.
In this project we will conduct a thorough proof of market analysis to identify the most
valuable disease targets against which we will build future drug development projects.
Furthermore, we will identify and initiate key relationships with potential customers, and
develop a comprehensive project plan in order to secure the necessary support to begin
making the medicines of the future.</gtr:abstractText><gtr:fund><gtr:end>2016-06-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2015-11-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>24998</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">700639</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>